SLC7A6

Across TCGA pan-cancer cohorts, SLC7A6 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SLC7A6 data layer compared with 26 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher SLC7A6 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SLC7A6 expression acts as an unfavorable survival marker.

LUAD, MESO, and LUSC are the cancer types where SLC7A6 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.017	0.812	<.001	24	view →
MESO	DFS	Median	III,IV	0.082	0.414	.007	18	view →
LUSC	OS	Median	II,III,IV	0.114	0.745	<.001	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SLC7A6–LUAD (OS)

Open the LUAD breakdown →